2026-10-29 20:50:00 UTC#540860newconfirmednews
BLCO stock news
BLCO stock news. Deduplicated factual headlines, scored for importance, with entity sentiment and the sectors, countries, and asset classes affected. Updates open into the storyline.
See the full wire20 wire items
2026-10-29 19:53:38 UTC#540267newconfirmednews
Citigroup maintains Bausch & Lomb at Buy, raises price target to $23 from $21
2026-10-29 19:15:49 UTC#540044newconfirmednews
RBC Capital maintains Bausch & Lomb at Outperform, raises price target to $23 from $21
2026-10-29 14:03:05 UTC#538021newconfirmednews
Wells Fargo maintains Bausch + Lomb at Equal-Weight, raises price target to $19 from $18
2026-10-29 11:14:23 UTC#536572newconfirmedpress release
Bausch + Lomb publishes multinational survey results on dry eye symptom prevalence and patient management
2026-10-28 19:20:00 UTC#531706newconfirmednews
Bausch + Lomb Corporation average analyst price target raised to $19.62, implying 11% upside
2026-10-28 13:54:58 UTC#529524newconfirmednews
Bausch + Lomb (BLCO) Q3 revenue up 8%, adjusted EBITDA +34%; FY 2026 guidance raised, net leverage at 4.1x
2026-10-28 11:57:05 UTC#528390newconfirmednews
Bausch + Lomb Corporation Q3 2026 earnings call commences
2026-10-28 11:51:00 UTC#528377updateconfirmednews
Bausch + Lomb Reports Q3 Net Income of $32 Million, Reaffirms Raised Full-Year 2026 Outlook
2026-10-28 10:58:25 UTC#527921newconfirmednews
Bausch + Lomb Q3 Revenue $1.375B, Up 7%; Raises Full-Year 2026 Guidance
2026-10-26 12:53:11 UTC#514743newconfirmednews
Bausch + Lomb Corp Q3 2026 earnings preview: analysts expect 22 cents EPS and $1.373 billion revenue
2026-10-16 20:11:00 UTC#473918newconfirmednews
Alcon Receives FDA Approval for Brytly Eye Drops for Redness Relief
dow_jonesimportance 0.40trust 0.90Alcon Inc. +0.60Food and Drug Administration +0.40Brytly +0.60+2 entities
2026-10-12 13:16:28 UTC#446783duplicateconfirmednews
Bausch + Lomb names Thomas J. Appio interim CEO as Brent Saunders departs; company signals 2026 guidance hike
reutersimportance 0.30trust 0.80Bausch + Lomb Corporation +0.20Bausch Health Companies Inc. +0.20Thomas J. Appio +0.30
2026-10-12 12:45:43 UTC#446620duplicateconfirmednews
Bausch + Lomb CEO Brent Saunders departs; Chairman Thomas Appio named interim chief
2026-10-12 12:42:27 UTC#446574duplicateconfirmednews
Bausch + Lomb CEO Brent Saunders departs; Chairman Thomas Appio named interim chief
reutersimportance 0.40trust 0.90Bausch + Lomb Corporation -0.20Brent Saunders -0.20Thomas Appio +0.10+2 entities
2026-10-12 11:35:53 UTC#446262duplicateconfirmednews
Bausch + Lomb names Thomas Appio interim CEO, signals 2026 guidance hike
2026-10-12 10:47:00 UTC#445947newconfirmednews
Bausch + Lomb CEO Brent Saunders to depart company following mutual agreement with board
2026-10-12 10:45:00 UTC#445956updateconfirmednews
Thomas J. Appio to retain Bausch Health CEO role while leading Bausch + Lomb as interim CEO
dow_jonesimportance 0.50trust 0.90Bausch + Lomb Corporation +0.20Bausch Health Companies Inc. +0.20Thomas J. Appio +0.20
2026-10-12 10:45:00 UTC#445955updateconfirmedpress release
Bausch + Lomb appoints Thomas J. Appio as interim CEO, expects to raise 2026 full-year guidance
dow_jonesimportance 0.60trust 1.00Bausch + Lomb Corporation +0.20Bausch Health Companies Inc. +0.20Thomas J. Appio +0.20
2026-10-07 12:23:00 UTC#425489newconfirmednews